Patient enrollment complete in Metadoxine Phase 3

Alcobra ( ADHD +1.1% ) completes patient enrollment for its Phase 3 clinical trial evaluating the safety and efficacy of Metadoxine Extended Release (MDX) in adult ADHD patients. The trial is a 300-patient, randomized placebo-controlled study at 18 sites in the U.S. and two sites in Israel. The primary endpoint is a statistically significant improvement in ADHD symptoms versus placebo as …

from Content Keyword RSS http://ift.tt/1npjndM http://ift.tt/eA8V8J

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s